CBD, together with a TRPV1 antagonist, reduces L-DOPA-induced dyskinesia in a model of Parkinson’s disease by acting on CB1R and PPARγ and reducing the expression of the inflammatory marker’s cyclooxygenase-2 (COX-2) and NFκB [126]. Here, PTGS2 is linked to drug-induced dyskinesia.